Translationally controlled tumour protein TCTP (gene symbol: TPT1) is a highly-conserved, cyto-protective protein implicated in many physiological and disease processes, in particular cancer, where it is associated with poor patient outcomes. To understand the mechanisms underlying the accumulation of high TCTP levels in cancer cells, we studied the signalling pathways that control translation of TCTP mRNA, which contains a 5'-terminal oligopyrimidine tract (5'-TOP). In HT29 colon cancer cells and in HeLa cells, serum increases the expression of TCTP two-and four-fold, respectively, and this is inhibited by rapamycin or mTOR kinase inhibitors. Polysome profiling and mRNA quantification indicate that these effects occur at the level of mRNA translation. Blocking this pathway upstream of mTOR complex 1 (mTORC1) by inhibiting Akt also prevented increases in TCTP levels in both HeLa and HT29 colon cancer cells, whereas knockout of TSC2, a negative regulator of mTORC1, led to derepression of TCTP synthesis under serum starvation. Overexpression of eIF4E enhanced the polysomal association of the TCTP mRNA, although it did not protect its translation from inhibition by rapamycin. Conversely, expression of a constitutively-active mutant of the eIF4E inhibitor 4E-BP1, which is normally inactivated by mTORC1, inhibited of TCTP mRNA translation in HEK293 cells. Our results demonstrate that TCTP mRNA translation is regulated by signalling through the PI3-K/Akt/mTORC1 pathway. This explains why TCTP levels are frequently increased in cancers, since mTORC1 signalling is hyperactive in ~80% of tumours.
Introduction
Translationally controlled tumour protein TCTP, the product of the TPT1 gene, also referred to as histamine-releasing factor (HRF) or fortilin, is a highly-conserved, multifunctional protein, which has been implicated in a range of both cell physiological and disease processes [1] [2] [3] [4] .
One of the best-established roles of TCTP is its anti-apoptotic, or more generally cytoprotective, function in cellular responses to a wide range of stresses, such as oxidative stress, heat shock, Ca ++ -stress, or stress induced by heavy metals or drug treatment [2] . This is underscored by the finding that gene knockout of TCTP in mice is embryonically lethal, due to excessive apoptosis early in embryogenesis [5] [6] [7] . TCTP has been found to bind to microtubules [8] and actin filaments [9] , and to a range of other proteins [10] . TCTP has been implicated in the regulation of cell division [11] , DNA damage repair [12] , protein synthesis [13] , and in the early development of both animals and plants [11, 14] .
There is now substantial evidence demonstrating that TCTP is related to cell growth and to the development of cancer [1] [2] [3] 15] TCTP is overexpressed in many cancer cell lines, and its protein levels are positively related to properties of these cells relating to growth behaviour, apoptosis prevention and tumorigenicity [1, 2] , and even metastatic potential [3, 15] . Increased TCTP levels are detected in a range of human tumours [2, 3, 15] , and a high TCTP status has been proposed as a prognostic marker for a poor outcome in breast cancer [16] , hepatocellular cancer [17] , and in gliomas [18] . A solid understanding of how TCTP levels are regulated in cancer cells is therefore urgently required. Extensive work on the experimental 'tumour reversion model' has shed light on the importance of TCTP in cancer development [15, 19] , and its anti-apoptotic activity, including the demonstrated antagonism to the tumour suppressor protein p53 [16, 20, 21] , has been proposed as an underlying mechanism. Alternative mechanisms by which TCTP exerts its anti-apoptotic activity have been proposed as [2, 22] .
Several reports indicated that TCTP might be involved in growth signalling pathways; for
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4 example, overexpression of TCTP in HeLa cells resulted in activation of phospholipase C-, as well as the mitogen-activated protein (MAP)-kinase and phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (Akt) pathways [23] . Other investigations demonstrated that knock-out of TCTP reduces cell size and general growth in Drosophila [24] . These authors concluded that TCTP is an upstream regulator of mTORC1 (mammalian target of rapamycin complex 1); however, other studies obtained different results in mammalian cells [25, 26] , so this point remains controversial.
The earliest observations published on TCTP, at the time designated Q23 [27] , p21 [28] or p23 [29] , described the rapid growth induction of its synthesis at the translational level as a main feature of the protein, supporting the notion that TCTP is important for cell growth [30] . Although it has meanwhile been established that TCTP levels may also be regulated by mechanisms other than translational control [1, 2] , the cellular response to growth stimuli typically involves translational up-regulation of TCTP levels, at least in mammalian cells. However, the precise signalling pathway and mechanism involved are not yet completely characterised. We have previously shown that eukaryotic initiation factor 4E (eIF4E) is involved in regulating TCTP levels after serum stimulation of mouse fibroblasts [31] . At this time, the link between mTORC1 and the regulation of eIF4E had not yet been established, and it is now important to examine whether translation of the TCTP mRNA is indeed regulated through the PI3-K/Akt/mTORC1 signalling pathway, which is frequently hyperactive in human tumours.
mTORC1 is the hub of a signalling network that integrates a wide range of environmental signals and regulates an array of important cellular processes, in particular anabolic pathways [32] . The best characterised role of mTORC1 is in growth signalling and the regulation of protein synthesis. Growth factor binding to tyrosine kinase receptors results in activation of mTORC1
typically through the PI3-K/Akt signalling pathway [32] [33] [34] , although the MAP kinase or Wnt signalling pathways can also regulate mTORC1 [35, 36] . A key intermediary player is the small A C C E P T E D M A N U S C R I P T phosphorylation are yet to be fully elucidated, whereas the importance of 4E-BP1 inactivation for the control of cap-dependent translation, cell proliferation and tumour development is well established [32, 40] . Activation of eIF4E through the PI3-K/Akt/mTORC1 signalling pathway is believed to enhance selectively the translation of mRNAs encoding proteins involved in important biological processes that contribute to cancer development: protein synthesis and ribosome biogenesis, energy metabolism, cell cycle activation, prevention of apoptosis, as well as promotion of angiogenesis and metastasis [32] . Translation of a particular subset of mRNAs, called TOP-mRNAs (based on the presence of a 5'-tract of oligopyrimidines, 5'-TOP), is specifically up-regulated upon mTORC1 activation, although the exact mechanism for this still remains to be elucidated [41, 42] . The mRNAs for ribosomal proteins and translation factors [43] [44] [45] are the classical representatives of this group, but recently also mRNAs for other proteins where shown to bear this signature [45] . The mRNA coding for TCTP also contains a 5'-TOP [14, 30, 46] ; in fact several potential TOP sequences were identified in the vicinity of its transcription start site [45] . Therefore, we hypothesised that its translation is specifically A C C E P T E D M A N U S C R I P T 
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Materials and Methods
Cell culture and treatments
HeLa cells and HT29 colon cancer cells were grown in DMEM (Dulbecco's Modified Eagle's Medium) supplemented with 10% foetal bovine serum (FBS), glutamine and 1% penicillin/streptomycin. For growth-induction experiments, cells were seeded in 6-well plates and grown to about 70% confluence; cells were then serum-starved for a minimum of 20h.
Growth-induction was performed by addition of 20% FBS for the indicated periods of time.
Where indicated, the following mTOR inhibitors were added 30 min prior to serum stimulation: 50 nM rapamycin (kindly provided by Selleck Chemicals, Houston, TX USA, to UAB), 100 nM AZD8055 (purchased from Selleck), 1 M PP242 (Sigma-Aldrich) or 5 M Akt inhibitor VIII (Calbiochem-Merck, Kilsyth, VIC Australia; the company's datasheet states that this inhibitor targets all three isoforms of Akt).
Cell lysis
For preparation of extracts, HeLa cells were washed three times with ice-cold PBS, lysed on the plates by scraping in about 120 l lysis buffer (50 mM Tris/HCl, 50 mM 2-glycerophosphate, 1 mM EGTA, 1 mM EDTA and 1% (v/v) Triton X-100, freshly supplemented with 2- 
Western blotting
Equal amounts of cell extract (typically 15 g total protein) were separated by SDS-gel electrophoresis on 12.5% polyacrylamide gels and electrophoretically transferred onto 
Antibodies
The mouse monoclonal anti-TCTP antibody (AB58362) was purchased from Abcam (UK) via 
Polysome profiles and Northern blot analyses
To generate polysome profiles, cytoplasmic cell extracts were layered onto 20-50% (w/v) sucrose gradients and centrifuged for 150 min at 37,000 rpm (240 000 x g) at 4 o C in a Beckman
rotor. Gradients were pumped out by upward displacement and fractionated into nine fractions. The absorbance at 254 nm was continuously monitored. RNA was isolated from each gradient fraction and processed for Northern blot analysis as previously described [49] .
Radioactive probes were prepared by the random primer technique using DNA fragments isolated from plasmids containing PCR-amplified cDNA sequences. Northern blots were visualised and quantified using a Typhoon phosphorimager (GE Healthcare, Hatfield, Herts, UK).
Quantification of TCTP mRNA by qPCR
HeLa cells were grown in 12-well plates to about 70% confluence. Cells were then serumstarved for 21 h. A subgroup of samples was re-stimulated for 6 h by addition of 20% FBS.
Where indicated, the mTOR inhibitors rapamycin (100 nM), PP242 (1 M) or AZD8055 (100 nM)
were present for the same time period, also in the case of serum-starved cells. All treatments effects on mRNA expression levels were assessed using one-way ANOVA for each target.
Statistical significance was accepted at P<0.05 and data are presented as the mean ± standard error of the mean.
Overexpression studies
To overexpress initiation factor eIF4E, HeLa cells were transiently transfected with a plasmid for the expression of HA-tagged human eIF4E [50] using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. The medium was changed after 5h and the cells were then maintained in medium containing 10% foetal calf serum for 48h.
HEK293 cells tetracycline-inducible for the expression of eIF4E or for the expression of a nonphosphorylatable (constitutively-active) mutant of 4E-BP1 were obtained from the lab of Dr
Simon Cook (Babraham Institute, UK) [51] . Cells were induced for the expression of the respective protein by incubation with tetracycline (1 g/ml) for 48 h prior to performing the experiment. 
Results
Growth factor-dependent induction of TCTP synthesis in cancer cells
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10 Serum-stimulation of mouse fibroblasts was originally used to demonstrate the growth factordependent regulation of TCTP synthesis [27] . We performed serum-starvation and refeeding experiments on HT29 colon cancer cells to study the regulation of TCTP synthesis, in presence or absence of rapamycin, the classical inhibitor of mTORC1 (Fig. 1A ). Serum stimulation resulted in an about two-fold increase in TCTP levels in HT29 cells, which was completely inhibited by rapamycin, indicating that mTORC1 indeed regulates TCTP expression in colon cancer cells. As an indication for mTORC1 activity, we also analysed the phosphorylation of RpS6 on serine residues 240/244, specific targets for p70-S6 kinase, which is activated by mTORC1. The observation that RpS6 phosphorylation is fully inhibited by rapamycin indicates that mTORC1 is indeed inactivated by this treatment in HT29 colon cancer cells.
Next, we chose HeLa cells to see whether the rapamycin-sensitive induction of TCTP synthesis is also observed in other cancer cell types. We found that the response to serum stimulation in terms of relative increase of cellular TCTP levels is about four-fold in these cells (Fig. 1B) , which resembles the level of induction previously observed in murine cell lines [29, 54] . We also [58]. In contrast to rapamycin, these mTOR kinase inhibitors do completely block serum-induced TCTP accumulation in HeLa cells (Fig. 1B) , which further confirms that mTOR is likely to be involved in the regulation of TCTP synthesis under these conditions. On the other hand, the incomplete effect of rapamycin in blocking the increase in TCTP levels does not reflect a partial effect of this drug, since RpS6 phosphorylation was completely inhibited by rapamycin (results
11 not shown). Rather, additional, rapamycin-insensitive but mTOR-dependent signalling events appear to be involved.
The accumulation of the TCTP protein after serum stimulation of cells could principally be due to protein stabilisation and/or an increased rate of synthesis. In a recent study, we applied the method of pulsed stable isotope labelling with amino acids in cell culture (pSILAC) to assess the relative rate of synthesis of individual proteins in HeLa cells over a period of 6 h, in the presence or absence of rapamycin or the mTOR-KIs PP242 or AZD8055 [59] . This method measures the de novo rate of accumulation of specific proteins, which are identified and quantitated by mass spectrometry. In this way, we generated a large dataset that allowed us to distinguish which proteins are specifically regulated through mTORC1, i.e., whose rates of synthesis are sensitive to inhibition by rapamycin or mTOR-KIs, from those ones that are not. Inspection of this dataset revealed that TCTP mRNA behaves like known TOP mRNAs, in that the rate of synthesis of TCTP is inhibited by rapamycin (about 50%) and more strongly (about 80%) by the mTOR-KIs PP242 or AZD8055 (Fig. 1C) . In contrast, the degree of inhibition by mTOR-KIs for proteins encoded by non-TOP mRNAs, such as hnRNP-A3 (right panel), is typically much weaker (in the range of 40%), and the inhibition by rapamycin of the synthesis of this and other proteins encoded by non-TOP mRNAs is on average only about 14% [59].
Serum induction of TCTP synthesis occurs at the level of translation and is completely inhibited by mTOR kinase inhibitors
The pSILAC data demonstrate that the serum-induced increase in TCTP levels is likely due to an increase in its rate of synthesis and the results with the mTOR kinase inhibitors indicate that this is driven by mTORC1 signalling. To assess whether the observed regulation of TCTP synthesis is associated with alterations in TCTP mRNA levels, we subjected HeLa cells to the same conditions as employed for Western blot analysis (Fig. 1B) , i.e. serum-starvation and 6 h
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12 refeeding with 20% FBS, both in the presence or absence of mTOR kinase inhibitors, and performed TCTP mRNA quantification by Real-Time-qPCR ( Fig. 2A) . The results clearly show that TCTP mRNA levels are not affected by serum starvation/refeeding or by mTOR kinase inhibitors.
To demonstrate that the increase in TCTP synthesis is actually regulated at the level of translation of its mRNA, we monitored the polysomal distribution of TCTP mRNA in the presence and absence of mTOR inhibitors. In such experiments, translationally active polysome-associated mRNAs are resolved from non-polysomal mRNAs. This is detected by
Northern blotting of the corresponding fractions from the sucrose density gradient ( (Fig. 2C ). This shift of the TCTP mRNA into polysomes is strongly inhibited by rapamycin and is completely prevented by the mTOR-KIs AZD8055 or PP242. This behaviour is very similar to that of the mRNA for RpS7, an established TOP mRNA,
13 although the shifts into and out of polysomes are more pronounced in the case of the ribosomal protein mRNA (from 30 to 70%; Fig. 2C ). In contrast, the mRNA for hnRNP-A3 displayed a completely different behaviour; at least 60% of this mRNA remained in polysomes under all conditions tested; and none of the mTOR inhibitors substantially affected its polysomal association. These results clearly demonstrate that the TCTP mRNA behaves as a typical TOP mRNA, in that it is regulated at the level of recruitment into polysomes, i.e. at translation initiation, by mTORC1 signalling (Fig. 2B,C) . Thus, mTOR signalling positively regulates the translation of the TCTP mRNA, but not its level of expression ( Fig. 2A) .
TCTP synthesis is regulated by the Akt pathway upstream of mTORC1
We then asked whether elements of the signalling pathway upstream of mTORC1 participate in the growth-dependent regulation of TCTP synthesis. First, we used Akt inhibitor VIII (Calbiochem), which inhibits all three Akt isoforms, to see whether it prevents serum-induced increase of TCTP levels in HeLa cells. Probing immunoblots with antibodies specific for phospho-Akt (Ser473) showed that Akt phosphorylation is indeed blocked under these conditions (Fig. 3A , right graph), in some blots even completely. This compound blocked the serum-induced accumulation of TCTP in HeLa cells, similarly to mTOR kinase inhibitors (Fig. 3A, left graph). Since we were particularly interested to probe whether the PI3-K/Akt pathway is involved in regulating TCTP levels in colon cancer cells, we also tested the effect of the Akt inhibitor on TCTP levels in HT29 cells. As shown in Fig. 3B , it fully blocked the ability of serum to increase TCTP protein levels.
Active Akt phosphorylates and inactivates the TSC complex, an important inhibitor of mTORC1, it therefore promotes mTORC1 signalling.To study the influence of the TSC complex on TCTP protein expression, we made use of mouse embryonic fibroblasts (MEFs) from TSC2-knockout and corresponding wild-type animals (Fig. 4) . The results clearly demonstrate that the A C C E P T E D M A N U S C R I P T expression levels of TCTP are generally two-fold higher in the TSC2-KO cells compared to wildtype cells. We also observed that TCTP levels are down-regulated during serum-starvation (the 0 h time-point) in wildtype cells, whereas this effect is not seen TSC2-KO cells (Fig. 4 , left graph and top western blot). Monitoring the levels of RpS6 phosphorylation (Fig. 4 , right graph and bottom western blot) confirmed that, as expected, mTORC1 signalling is constitutively activated in TSC2-KO cells, including in serum-starved cells (0 h), whereas it is very low in serum-starved wildtype cells. Taken together, the data in Figs. 3 and 4 imply that both the tuberous sclerosis complex and Akt participate in the serum-dependent regulation of TCTP levels.
The downstream targets of mTORC1, 4E-BP1
, and its binding partner, initiation factor eIF4E, are involved in regulating TCTP mRNA translation.
The best-characterised output of mTORC1 activity that impinges on mRNA translation initiation is the phosphorylation and concomitant inactivation of 4E-BP1, resulting in the increased availability of eIF4E to engage in translation initiation [42, 61] . To initially assess whether eIF4E plays a role in regulating TCTP mRNA translation, we transiently transfected HeLa cells with a vector encoding HA-tagged human eIF4E and analysed the polysomal distribution of TCTP mRNA in cells with and without overexpressed eIF4E. In this system, eIF4E overexpression caused a substantial increase in the polysomal association of TCTP mRNA ( Fig. 5 ; left panels).
This effect was reversed by treatment with rapamycin, indicating that eIF4E is unable to override the inhibitory effect of this mTORC1 inhibitor. We also probed the blots for the mRNA for RpS7, another TOP-mRNA, and found that it behaved very similarly to the TCTP mRNA ( To assess the importance of eIF4E and 4E-BP1 for the control of TCTP mRNA translation, we also made use of HEK293 cells engineered to be tetracycline (tet)-inducible for the expression
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15 of eIF4E or a constitutively active mutant of 4E-BP1, respectively [51] . Fig. 6A demonstrates that overexpression of eIF4E in HEK293 cells resulted in an about 1.3-fold increase in the polysomal association of TCTP mRNA, which is prevented in the presence of rapamycin.
Compared to the situation observed in HeLa cells (Fig. 5) , the relative shift of the TCTP mRNA into polysomes and its inhibition by rapamycin was less pronounced in these cells. The mRNA for RpS6, another TOP message, displayed a similar behaviour, although the polysomal shift caused by eIF4E overexpression and the effect of rapamycin was more pronounced for this mRNA, compared to TCTP mRNA. In contrast, the (non-TOP) actin mRNA was already heavily associated with polysomes and its polysomal association was only affected to a small extent by overexpressing eIF4E or by rapamycin (Fig. 6A ). Expression of a constitutively active (phosphorylation-defective) mutant of 4E-BP1 in HEK293 cells resulted in a similar (20-30%)
inhibition of polysomal association of all three mRNAs (Fig.6A ). This indicates that 4E-BP1 does play a role in regulating the translation of the TCTP mRNA, but that this reflects a rather general effect, not one specific for TOP mRNAs. Further data for Rp and actin mRNAs obtained with this tet-inducible HEK293 cell system have been submitted elsewhere for publication.
We also tested whether the activation of translation of the TCTP mRNA by increased eIF4E levels is reflected in TCTP protein levels. Expression of eIF4E was induced in HEK293 cells by treatment with tetracycline for 48 h. Cells were then subjected to serum-starvation and subsequent re-feeding. Under both conditions, TCTP protein levels were higher in eIF4E-overexpressing cells than in control cells (Fig. 6B) , confirming that eIF4E does promote TCTP expression, relative to that of actin, even under serum-starved conditions. We also tested the effect of the interfering mutant of 4E-BP1 on TCTP expression levels by Western blotting and found that it substantially reduced TCTP levels in HEK293 cells (Fig. 6C ). Taken together, these studies demonstrate that 4E-BP1 levels and eIF4E availability can both contribute markedly to regulating TCTP expression.
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Discussion
Initial evidence for the translational regulation of TCTP synthesis came from the observation that the TCTP (P21) mRNA is stored in cytoplasmic untranslated mRNP particles [28] , and from the rapid induction by serum in the rate of TCTP ('Q23' or 'P23') synthesis, which is not impaired by inhibitors of transcription, such as actinomycin D [29] . However the mechanism(s) regulating the translation of its mRNA had not previously been fully characterised.
Demonstration of the importance of initiation factor eIF4E for the translational regulation of growth-regulatory mRNAs [62] prompted us to study the involvement of this factor in the control of TCTP (P23) synthesis, which provided evidence in support of this [31] . At that time, the prevailing view was that eIF4E activity is particularly required for highly structured mRNAs that are otherwise poorly translated [63] , and the link between the mTORC1 pathway and control of eIF4E availability was only established later.
A characteristic feature of the TCTP mRNA is the presence of a 5'-TOP [14, 30, 45, 46] , which is found in many mRNAs whose translation is controlled through mTORC1 signalling. This prompted us to undertake the present study, which was aimed at exploring the involvement of the Akt/mTORC1 signalling pathway in the translational regulation of TCTP synthesis in cancer cells. In both HT29 colon cancer cells (Fig.1A ) and HeLa cells (Fig. 1B) , the allosteric mTORC1 inhibitor rapamycin substantially inhibited serum-dependent TCTP accumulation, but in HeLa cells it did not do so completely. In contrast, two recently-developed mTOR kinase inhibitors, PP242 and AZD8055, each completely inhibited the induction of TCTP in HeLa cells (Fig. 1B) . 
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The data obtained for TCTP by this method support the conclusion that de novo synthesis of TCTP is positively regulated by mTORC1 activity (Fig. 1C) . Two other studies used ribosome profiling in combination with deep-sequencing to generate transcriptome-wide datasets of mTORC1-regulated mRNAs [64, 65] . Compilation of the results for the TCTP mRNA/protein from all three papers (Table 1) shows that for TCTP, both methods yield very similar results, indicating that all mTOR kinase inhibitors tested (Torin 1, PP242 and AZD8055) inhibit TCTP mRNA translation by at least 80% (more strongly than many other TOP mRNAs), whereas rapamycin resulted in only slightly more than 50% inhibition (similar to many other TOP mRNAs).
Similar results were obtained in all three mammalian cell types investigated (Table 1) . These data also correspond well with our findings for HeLa cells, demonstrating (1) that the seruminduced increase in TCTP levels is inhibited by around 50% by rapamycin and completely prevented by mTOR-KIs (Fig.1B) and (2) that this effect involves translational up-regulation (recruitment of the mRNA into polysomes) which is prevented by mTOR-KIs (Fig. 2B ).
We also asked whether components upstream of mTORC1 are involved in growth-dependent up-regulation of TCTP synthesis. An inhibitor of Akt, a kinase which indirectly activates mTORC1 by phosphorylating TSC2, completely prevented induction of TCTP in both HeLa (Fig.   3A ) and HT29 colon cancer cells (Fig. 3B) . The latter finding also supports our hypothesis that the increased expression levels of TCTP observed in adenocarcinomas of the colon (our unpublished immunohistochemistry results) are likely to be caused by increased signalling through the PI3-K/Akt pathway, an effect which is frequently observed in colon cancer [52, 53] .
Similar to the observations of [66], we find that MEFs from TSC2-knockout mice have lost their ability to repress both mTORC1 activity (assessed by monitoring RpS6 phosphorylation) and TCTP synthesis in response to serum starvation (Fig. 4) . Overall, the results obtained with the Akt inhibitor and with the MEFs from TSC2-KO mice clearly support the view that TCTP synthesis is regulated through these upstream regulators of mTORC1.
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We also studied the effect of downstream effectors of mTORC1 on TCTP mRNA translation.
Since activation of mTORC1 increases the availability of eIF4E through inactivation of 4E-BP1
[42, 61], we asked whether increased levels of eIF4E contribute to activation of TCTP mRNA translation and whether it is impaired by increased activity of 4E-BP1. Our results demonstrate that increased eIF4E levels are able to drive the TCTP mRNA into heavy polysomes in both HeLa cells (Fig. 5 ) and HEK293 cells (Fig.6A ), although the extent to which this occurs differs between different the two cell lines. Generally, we observe in our polysome profiling experiments (Figs. 2, 5 and 6 ) that the responses of the TCTP mRNA to alterations of cellular conditions (in terms of polysome shift) are less than that of the ribosomal protein mRNAs, the classical TOP mRNAs. However, the general pattern of behaviour (response to serum stimulation or sensitivity to mTOR inhibition) is very similar between TCTP mRNA and Rp mRNAs, which underscores the classification of TCTP mRNA as a TOP-mRNA.
The polysome profiling results obtained from HeLa cells (Fig. 5) show that, in this cell line, eIF4E overexpression cannot overcome the inhibitory effects of rapamycin, indicating that additional mechanisms are involved in the mTORC1-dependent regulation of TCTP mRNA translation. Our results obtained by Western blotting (Fig. 6B ) confirm that eIF4E levels do indeed have a considerable effect on TCTP protein accumulation in HEK293 cells. They also show that eIF4E can partially overcome the inhibitory effect of serum starvation on TCTP protein levels, complementing our earlier findings obtained in murine fibroblasts overexpressing eIF4E [31] .
Since 4E-BP1, rather than eIF4E itself, is the direct target of mTORC1, we also asked whether 4E-BP1 affects TCTP mRNA translation. Our results show that expression of a constitutivelyactive mutant of 4E-BP1 in HEK293 cells resulted in the partial release of the TCTP mRNA from heavy polysomes (Fig. 6A) , and also in a significant reduction of cellular TCTP levels (Fig. 6C ).
These findings clearly establish the involvement of 4E-BP1 in the control of TCTP mRNA translation. The response of another TOP mRNA (for RpS6) to increased 4E-BP1 activity is A C C E P T E D M A N U S C R I P T similar to that of TCTP mRNA. We also observed that the polysomal association of the (non-TOP) actin mRNA, was significantly decreased by mutant 4E-BP1 (Fig. 6A ). This indicates that the effect of 4E-BP1 is a rather general one and is not restricted to TOP-mRNAs. This point requires future investigation, particularly in the light of recent data indicating that the eIF4E/4E-BP system is unlikely to be involved in the oxygen-dependent regulation of TOP mRNA translation via mTORC1 [67] .
Taken together, the present data strongly support the conclusion that the TCTP mRNA belongs to the set of 5'-TOP mRNAs, the translation of which is specifically regulated through the There is overwhelming evidence that the PI3-kinase/Akt/mTORC1 pathway is closely linked to tumorigenesis [32, 36, 48, 52, 53] . In particular, the 4E-BP1/eIF4E axis downstream of mTORC1 has been implicated in promoting cancer, through the translational activation of mRNAs encoding proteins involved in cell proliferation [40] and in tumour initiation and metastasis [64] . Importantly, two reports stress the importance of mTOR-dependent
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20 translational activation of the anti-apoptotic protein Mcl-1 for cell survival [47] and for cancer initiation and progression [48] . As a further anti-apoptotic protein involved in cancer progression A C C E P T E D M A N U S C R I P T A C C E P T E D M A N U S C R I P T Bommer et al, Table 1 .
Figure legends
